Citius Pharmaceuticals Inc. (CTXR), headquartered in Cranford, New Jersey, is a dynamic biopharmaceutical company dedicated to advancing innovative therapies targeting critical care environments. With a strong pipeline aimed at addressing substantial unmet medical needs, Citius focuses on enhancing patient outcomes through its cutting-edge technologies and strategic collaborations. Positioned to become a key player in the critical care sector, the company embodies a commitment to innovation and growth, presenting a compelling opportunity for institutional investors seeking to capitalize on advancements in the biopharmaceutical landscape. Show more

Location: 11 COMMERCE DRIVE, CRANFORD, NJ, UNITED STATES, 07016, Cranford, NJ, 07016, USA | Website: https://citiuspharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

16.56M

52 Wk Range

$0.63 - $2.97

Previous Close

$0.77

Open

$0.75

Volume

265,237

Day Range

$0.74 - $0.78

Enterprise Value

14.79M

Cash

4.252M

Avg Qtr Burn

-11.88M

Insider Ownership

2.37%

Institutional Own.

10.44%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LYMPHIR (Denileukin Diftitox-cxdl, E7777) Details T-cell lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mino-Lok Details Catheter related blood stream infections	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Halo-Lido (CITI-102) Details Hemorrhoids	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Pembrolizumab (KEYTRUDA®) + LYMPHIR™ Details Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.